TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Pain score during knee flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of any adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: False negative management failures
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Clinical Malaria Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: adverse events and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: local tolerability (liver enzymes, blood glucose, uric acid)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consumption of Fentanyl
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Respiratory system compliance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Columbia Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Behavioural, Neurocognitive Measures Using Vineland Adaptive Behaviour Scale (VABS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preoperative Kmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: posterior elevation of the thinnest point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cone location
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lars score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Moderate/Vigorous Intensity Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart Failure Related Health Status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Visual Analogue Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: rates of pregnancy and out-of-wedlock child birth
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: educational achievement, including graduation from high school and participation in various types of post-high school education
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: participation in the work force, including enrollment in the armed services
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Functional Mobility Scale (FMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gross Motor Function Measurement (GMFM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BTS G-Walk Spatiotemporal Gait Analysis System
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants finishing the study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of detection of discontinuous (skip) lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of SADEs
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of ischemic strokes
Endpoint domain: Mortality/survival
Primary endpoint: Intramyocardial lipid content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Subjects Reporting Fever
Endpoint domain: Adverse events/effects
Primary endpoint: Visual Quality of small bowel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Diagnostic yield during capsule endoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: nipple areola complex necrosis
Endpoint domain: Adverse events/effects
Primary endpoint: Drug Related Problems (DRP)
Endpoint domain: Adverse events/effects
Primary endpoint: Visual analog scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Taiwanese version of Neuropathic pain symptom inventory (NPSI-T)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Taiwanese version of the Brief Fatigue Inventory (BFI-T)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Percentage of Subjects Achieving a 24 Hour Average Total Serum Testosterone Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cmax of EDP-938
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of EDP-938
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of total serious valve-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Peak gradient as assessed by echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean gradient as assessed by echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Valvular regurgitation as assessed by echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Final Clinical Cure for Index Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomarkers of molecular signature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Study Successes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colonization of Candida spp.
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Response rate in both arms
Endpoint domain: Physiological/clinical
Primary endpoint: change in lower leg volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Family Environment Scale
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Dyadic Adjustment Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hopkins Verbal Learning Task
Endpoint domain: Cognitive functioning
Primary endpoint: Change in Z-Alpha 1 Antitrypsin Liver Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Continent Patients Post Prostatectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cataracts
Endpoint domain: Adverse events/effects
Primary endpoint: Glaucoma
Endpoint domain: Adverse events/effects
Primary endpoint: Fractures (hip, wrist, vertebral)
Endpoint domain: Adverse events/effects
Primary endpoint: Invasive pneumococcal disease hospitalisation rates
Endpoint domain: Mortality/survival
Primary endpoint: Time to diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accuracy of artificial intelligence in diagnosing myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of histologically healthy margins maintained during resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Esophageal contractile properties
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in HSV-2 viral shedding rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade of the biocompatibility of the biomaterials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Characteristics of the immune response of the biomaterials in the host tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of degradation of the biomaterials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients presenting with haemoptysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Presence of ZIKV in semen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Difference in fasting and after load GLP1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Resource usage associated with planning and delivery
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Safety and clinical efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long term outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction in mucosal TNF-alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proper diagnosis of prolapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge Assessment Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Donor engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Diabetes and/or Glucose Intolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decrease in Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Change in Visual Acuity Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Hyperhidrosis Disease Severity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in low back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time to first CT scan
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Blood loss intra- and post-operative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Unexpected hospital readmission within 90 days from discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Duration of Ultrasound from Ordered to Completed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Aerosol Particle Concentrations 1-3 Micrometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aerosol Particle Concentrations <0.3 Micrometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aerosol Particle Concentrations 0.3-0.5 Micrometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aerosol Particle Concentrations 0.5-1 Micrometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aerosol Particle Concentrations 3-5 Micrometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of active tuberculosis
Endpoint domain: Mortality/survival
Primary endpoint: Visible Changes to the Vulva, Vestibule and Vaginal Region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Blood concentrations of lymphocyte populations, dendritic cells, monocytes, and granulocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum concentrations of cytokines and chemokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in PBMC gene expression relative to prevaccine levels of key genes expected to change, such as IP-10 and MCP-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Volume of brain structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: change in platelet aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants Who Responded to Intense Pulsed Light (IPL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Static Knee Stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Isokinetic Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: change in pain using a visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement of maximum voluntary mouth opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crossover rate from Radial to Femoral access
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Serum level of NT-proBNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Exercise capacity (NYHA, V02, 6 min walking test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risks to sexual function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: risks to urinary function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Summed Ocular Inflammation Score (SOIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic chest wall compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Airway Resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to First Symptoms of Moderate Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported continuous abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostate temperature measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Tibial Bone Mass Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Death all causes
Endpoint domain: Mortality/survival
Primary endpoint: Behavioral intentions to get a mammogram
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to Treatment for Attack
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total Duration of Attack
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success rate of external cephalic version
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Prevalence of chronic hepatitis C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Optimization of MRE methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean Pulmonary Artery Pressure (MPAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of weeks with adequate overall relief of IBS symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Framingham risk scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Reynolds Risk Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes at glycated hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent of Non Assessable Renal Artery Segments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Salivary Cotinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Longitudinal Strain Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients meeting MAKE30 criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects Experiencing Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of T2T patients achieving sustained CDAI LDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of RC patients achieving sustained CDAI LDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of oral symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior chamber cell
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anterior chamber flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Unadjusted Pearl Index
Endpoint domain: Mortality/survival
Primary endpoint: Incidence, intensity, relationship, and seriousness of treatment-emergent AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Aneurysm Growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from death or permanent neurological injury
Endpoint domain: Mortality/survival
Primary endpoint: Mean Length of Utterance in morphemes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Turn Length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of different vocabulary words spoken
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Evaluation of Language Fundamentals-5th edition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Malassezia spp.
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Device Technical Failure
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical Failure
Endpoint domain: Adverse events/effects
Primary endpoint: Number of days with severe respiratory disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: SARS-CoV-2 IgG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-SARS-CoV-2 IgG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Delta change in left ventricular ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Main cause of death
Endpoint domain: Mortality/survival
Primary endpoint: Alive/deceased
Endpoint domain: Mortality/survival
Primary endpoint: Change of the subjective International Knee Documentation Committee score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: increasing appropriate referrals to genetic counselors
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: increasing appropriate screening for breast, colon, and ovarian cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: appropriate risk-based management of thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Benefit of NP in acne treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline on MADRS Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Experiences of comfort during radiotherapy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum observed plasma concentration (Cmax) of BMS-986278
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) of total radioactivity (TRA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve extrapolated to infinity (AUC(INF)) of BMS-986278
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve extrapolated to infinity (AUC(INF)) of TRA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timely Viral Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: feasibility of uOCT probe
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of adverse events or safety outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Final Clinical Cure Rate for the Index Lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibrosis level of explanted mesh
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exacerbation of heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Oral Mucositis Severity - WHO Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral Mucositis Severity - NCI Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone union / fusion assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End of deformity correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of the surgeon and patients experience with the MAXFRAME™ system
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time of Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance Visual Acuity (VA) With Study Lenses - Completed Eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance Visual Acuity (VA) With Study Lenses - Discontinued Eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Ocular Serious and Significant Non-serious Adverse Device Effects (ADEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Total Oral Bacterial Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of C16G2 Gel Administrations
Endpoint domain: Adverse events/effects